@article{oai:nagasaki-u.repo.nii.ac.jp:00005025,
 author = {Motoshima, Kohei and Nakamura, Yoichi and Shimada, Midori and Kitazaki, Takeshi and Senju, Hiroaki and Ogawara, Daiki and Takemoto, Shinnosuke and Mizoguchi, Kosuke and Sato, Shuntaro and Nakatomi, Katsumi and Fukuda, Minoru and Kohno, Shigeru},
 issue = {2},
 journal = {Acta medica Nagasakiensia},
 month = {Jan},
 note = {Objective: Cisplatin is well known for producing severe adverse events, including renal dysfunction. To prevent renal dysfunction
caused by cisplatin, routine magnesium supplementation is recommended. However, few reports exist about the efficacy of
magnesium in preventing renal dysfunction. Therefore, the purpose of this study was to retrospectively survey the efficacy of
magnesium in preventing renal dysfunction after administration of cisplatin.
Methods: We evaluated patients who received first-line cisplatin-based chemotherapy from May 2008 to June 2013.
Results: Data from 146 patients and a total of 394 treatments was analyzed. Elevation of serum creatinine was detected in 77 /
394 treatments (19.5%). Statistical significance was found between prevention of elevation of serum creatinine and magnesium
supplementation. The other significant parameters were serum creatinine and eGFR levels before treatment and patient age. In
multivariate analysis, magnesium and eGFR before treatment were statistically significant.
Conclusions: The study results suggest that magnesium supplementation might reduce nephrotoxicity caused by cisplatin. The
eGFR level before treatment might be an important factor associated with nephrotoxicity after cisplatin administration., Acta medica Nagasakiensia, 60(2), pp.39-44; 2016},
 pages = {39--44},
 title = {The efficacy of magnesium in preventing renal dysfunction due to high-dose cisplatin for treatment of thoracic tumor},
 volume = {60},
 year = {2016}
}